Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [41] Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis
    Yun Liu
    Ying Zhang
    Jinhong Gao
    Lijuan Wang
    Fang Xie
    Chengtao Zhang
    Peimin Mao
    Jinsong Yan
    BMC Cancer, 25 (1)
  • [42] Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease
    Sanber, Khaled
    Ye, Kevin
    Tsai, Hua-Ling
    Newman, Matthew
    Webster, Jonathan A.
    Gojo, Ivana
    Ghiaur, Gabriel
    Prince, Gabrielle T.
    Gondek, Lukasz P.
    Smith, B. Douglas
    Levis, Mark J.
    DeZern, Amy E.
    Ambinder, Alexander J.
    Dalton, William B.
    Jain, Tania
    LEUKEMIA & LYMPHOMA, 2023, 64 (04) : 846 - 855
  • [43] Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies
    Rausch, Caitlin R.
    DiNardo, Courtney D.
    Kadia, Tapan
    Takahashi, Koichi
    Jain, Nitin
    Benton, Christopher
    Thompson, Philip
    Ohanian, Maro
    Covert, Wendy
    Mace, Morgan
    Marx, Kayleigh R.
    Pemmaraju, Naveen
    Daver, Naval
    Jabbour, Elias
    Cortes, Jorge
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Konopleva, Marina
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10) : S4 - S5
  • [44] Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia
    Zucenka, Andrius
    Griskevicius, Laimonas
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1227 - 1231
  • [45] AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
    Todisco, Elisabetta
    Papayannidis, Cristina
    Fracchiolla, Nicola
    Petracci, Elisabetta
    Zingaretti, Chiara
    Vetro, Calogero
    Martelli, Maria Paola
    Zappasodi, Patrizia
    Di Renzo, Nicola
    Gallo, Susanna
    Audisio, Ernesta
    Griguolo, Davide
    Cerchione, Claudio
    Selleri, Carmine
    Mattei, Daniele
    Bernardi, Massimo
    Fumagalli, Monica
    Rizzuto, Giuliana
    Facchini, Luca
    Basilico, Claudia Maria
    Manfra, Ilenia
    Borlenghi, Erika
    Cairoli, Roberto
    Salutari, Prassede
    Gottardi, Michele
    Molteni, Alfredo
    Martini, Vincenza
    Lunghi, Monia
    Fianchi, Luana
    Cilloni, Daniela
    Lanza, Francesco
    Abruzzese, Elisabetta
    Cascavilla, Nicola
    Rivellini, Flavia
    Ferrara, Felicetto
    Maurillo, Luca
    Nanni, Jacopo
    Romano, Alessandra
    Cardinali, Valeria
    Gigli, Federica
    Roncoroni, Elisa
    Federico, Vincenzo
    Marconi, Giovanni
    Volpi, Roberta
    Sciume, Mariarita
    Tarella, Corrado
    Rossi, Giuseppe
    Martinelli, Giovanni
    CANCER, 2023, 129 (07) : 992 - 1004
  • [46] Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients
    Borlenghi, E.
    Roccaro, A. M.
    Cattaneo, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (04) : 504 - 506
  • [47] Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Saiz-Rodriguez, Miriam
    Labrador, Jorge
    Martinez-Cuadron, David
    Sanz, Miguel A.
    Montesinos, Pau
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S306 - S306
  • [48] Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax plus Hypomethylating Agent
    Gangat, Naseema
    Elbeih, Azeem
    Ghosoun, Nour
    Mccullough, Kristen
    Aperna, Fnu
    Johnson, Isla M.
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Elliott, Michelle
    Mangaonkar, Abhishek
    Matin, Aasiya
    Saliba, Antoine N.
    Torghabeh, Mehrdad Hefazi
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Arana
    Yates, Samuel
    Sneider, Abigail
    Dworkin, Emily
    Patel, Anand A.
    Bazinet, Alexandre
    Senapati, Jayastu
    Bataller, Alex
    Dinardo, Courtney
    Kadia, Tapan
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (02) : 260 - 271
  • [49] Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
    Ghorab, Ahmad
    Litzow, Mark
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun
    Murthy, Hemant
    Alkhateeb, Hasan
    Begna, Kebede
    Patnaik, Mrinal
    Foran, James
    Badar, Talha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S306 - S306
  • [50] Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study
    Xu, Fangfei
    Zhou, Kuangguo
    Gong, Duanhao
    Huang, Wei
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
12345